• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immune Therapeutics Inc (OP: IMUN )

    N/A UNCHANGED
    Last Price Updated: 12:27 PM EDT, Oct 18, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Immune Therapeutics Inc

    Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky
    From Immune Therapeutics, Inc.
    Via GlobeNewswire
    Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV
    From Immune Therapeutics, Inc.
    Via GlobeNewswire
    Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH
    From Immune Therapeutics, Inc.
    Via GlobeNewswire
    Statera Biopharma Shares Fall After Taking Stake In Holographic Medical Imaging
    Via Benzinga
    Why Are Statera Biopharma Shares Surging Today
    Via Benzinga
    Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies
    The settlement between Statera Biopharma, Inc. and Biostax Corp. includes an amended royalty-bearing license agreement and a joint petition to dismiss the involuntary bankruptcy case against Statera... 
    From Immune Therapeutics, Inc.
    Via GlobeNewswire
    Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction
    From Immune Therapeutics, Inc.
    Via GlobeNewswire
    Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development
    From Immune Therapeutics, Inc.
    Via GlobeNewswire
    Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors
    From Immune Therapeutics, Inc.
    Via GlobeNewswire
    The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Good morning! We're gearing up for another busy day of trading with a breakdown of the biggest pre-market stock movers for Thursday! 
    Via InvestorPlace
    The 10 Most Shorted Stocks Right Now for Friday, Dec. 17
    Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we're diving into some top candidates! 
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.